Literature DB >> 9547946

Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II).

H Tamamura1, R Arakaki, H Funakoshi, M Imai, A Otaka, T Ibuka, H Nakashima, T Murakami, M Waki, A Matsumoto, N Yamamoto, N Fujii.   

Abstract

A tachyplesin peptide analog, T22 ([Tyr5,12, Lys7]-polyphemusin II), and its shortened congener, TW70 (des-[Cys8,13, Tyr9,12]-[D-Lys10, Pro11]-T22) have strong anti-human immunodeficiency virus (HIV) activity, comparable to that of 3'-azido-2', 3'-dideoxythymidine (AZT). T22 and TW70 are extremely basic peptides, containing 5 Arg residues and 3 Lys residues. The number of positive charges might be related in part to high collateral cytotoxicities of T22 and TW70. Here we have synthesized several analogs, in which the number of positive charges has been reduced through amino acid substitutions using Glu or L-citrulline. As a result, several effective compounds have been found which possess higher selectivity indexes (SIs, 50% cytotoxic concentration/50% effective concentration) than those of T22 and TW70. Higher SIs were attributed mainly to a decrease in cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9547946     DOI: 10.1016/s0968-0896(97)10037-2

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  12 in total

1.  T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.

Authors:  R Arakaki; H Tamamura; M Premanathan; K Kanbara; S Ramanan; K Mochizuki; M Baba; N Fujii; H Nakashima
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

Review 2.  Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors.

Authors:  Chaozai Zhang; Ruohan Zhu; Qizhi Cao; Xiaohong Yang; Ziwei Huang; Jing An
Journal:  Exp Biol Med (Maywood)       Date:  2020-02-04

3.  env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors.

Authors:  Valery Fikkert; Peter Cherepanov; Kristel Van Laethem; Anke Hantson; Barbara Van Remoortel; Christophe Pannecouque; Erik De Clercq; Zeger Debyser; Anne-Mieke Vandamme; Myriam Witvrouw
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

4.  Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.

Authors:  Federica Barbieri; Adriana Bajetto; Tullio Florio
Journal:  J Oncol       Date:  2009-12-14       Impact factor: 4.375

Review 5.  Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

Authors:  Hyunsuk Shim; Shinya Oishi; Nobutaka Fujii
Journal:  Semin Cancer Biol       Date:  2008-11-25       Impact factor: 15.707

Review 6.  The intricate role of CXCR4 in cancer.

Authors:  Samit Chatterjee; Babak Behnam Azad; Sridhar Nimmagadda
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

7.  PET imaging of CXCR4 receptors in cancer by a new optimized ligand.

Authors:  Oliver Demmer; Eleni Gourni; Udo Schumacher; Horst Kessler; Hans-Jürgen Wester
Journal:  ChemMedChem       Date:  2011-07-20       Impact factor: 3.466

Review 8.  Retrocyclins and their activity against HIV-1.

Authors:  W Todd Penberthy; Soumya Chari; Amy L Cole; Alexander M Cole
Journal:  Cell Mol Life Sci       Date:  2011-05-07       Impact factor: 9.261

Review 9.  The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review.

Authors:  Qi Chen; Tie Zhong
Journal:  Drug Des Devel Ther       Date:  2015-09-07       Impact factor: 4.162

10.  Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials.

Authors:  Naroa Serna; Aïda Falgàs; Annabel García-León; Ugutz Unzueta; Yáiza Núñez; Alejandro Sánchez-Chardi; Carlos Martínez-Torró; Ramón Mangues; Esther Vazquez; Isolda Casanova; Antonio Villaverde
Journal:  Pharmaceutics       Date:  2022-01-14       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.